Standard BioTools Inc. (LAB) stock
LABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 12/3087% below fair value
$0.64−0.02 (-3.31%)
Close on Nov 11, 2026Market cap $252.43MP/E 2.9Yield –
Standard BioTools gross margin
Gross margin is gross profit as a percentage of revenue.
Standard BioTools's gross margin for the twelve months ending Jun 30, 2026 was 50.5%. For fiscal 2025 it was 49.9%, against 49.3% the year before. The highest annual figure on record is 99.8% in fiscal 2011.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.9% | +0.5 |
| FY2024 | Dec 31, 2024 | 49.3% | +1.9 |
| FY2023 | Dec 31, 2023 | 47.4% | +9.6 |
| FY2022 | Dec 31, 2022 | 37.8% | −17.0 |
| FY2019 | Dec 31, 2019 | 54.8% | +0.3 |
| FY2018 | Dec 31, 2018 | 54.6% | +3.6 |
| FY2017 | Dec 31, 2017 | 51.0% | −5.0 |
| FY2016 | Dec 31, 2016 | 55.9% | −6.6 |
| FY2015 | Dec 31, 2015 | 62.5% | −37.2 |
| FY2014 | Dec 31, 2014 | 99.7% | +0.2 |
| FY2013 | Dec 31, 2013 | 99.6% | +0.2 |
| FY2012 | Dec 31, 2012 | 99.4% | −0.3 |
| FY2011 | Dec 31, 2011 | 99.8% | +34.3 |
| FY2010 | Dec 31, 2010 | 65.5% | +10.7 |
| FY2009 | Dec 31, 2009 | 54.8% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 52.4% | +3.6 |
| Q1 FY2026 | Mar 31, 2026 | 53.5% | −1.2 |
| Q4 FY2025 | Dec 31, 2025 | 47.8% | +2.0 |
| Q3 FY2025 | Sep 30, 2025 | 48.5% | −6.4 |
| Q2 FY2025 | Jun 30, 2025 | 48.8% | +2.7 |
| Q1 FY2025 | Mar 31, 2025 | 54.6% | +1.5 |
| Q4 FY2024 | Dec 31, 2024 | 45.8% | −1.5 |
| Q3 FY2024 | Sep 30, 2024 | 54.9% | +10.9 |
| Q2 FY2024 | Jun 30, 2024 | 46.1% | −3.0 |
| Q1 FY2024 | Mar 31, 2024 | 53.1% | +4.2 |
| Q4 FY2023 | Dec 31, 2023 | 47.4% | +6.1 |
| Q3 FY2023 | Sep 30, 2023 | 44.0% | +8.0 |
| Q2 FY2023 | Jun 30, 2023 | 49.2% | +25.6 |
| Q1 FY2023 | Mar 31, 2023 | 48.9% | −0.6 |
| Q4 FY2022 | Dec 31, 2022 | 41.3% | −10.9 |
| Q3 FY2022 | Sep 30, 2022 | 36.0% | −9.4 |
| Q2 FY2022 | Jun 30, 2022 | 23.6% | −23.5 |
| Q4 FY2020 | Dec 31, 2020 | 49.5% | −4.6 |
| Q3 FY2020 | Sep 30, 2020 | 52.2% | −0.0 |
| Q2 FY2020 | Jun 30, 2020 | 45.4% | −9.1 |
| Q1 FY2020 | Mar 31, 2020 | 47.1% | −9.3 |
| Q4 FY2019 | Dec 31, 2019 | 54.1% | −4.1 |
| Q3 FY2019 | Sep 30, 2019 | 52.2% | −2.4 |
| Q2 FY2019 | Jun 30, 2019 | 54.5% | +3.1 |
| Q1 FY2019 | Mar 31, 2019 | 56.4% | +3.2 |
| Q4 FY2018 | Dec 31, 2018 | 58.2% | +19.1 |
| Q3 FY2018 | Sep 30, 2018 | 54.6% | +0.8 |
| Q2 FY2018 | Jun 30, 2018 | 51.4% | −3.4 |
| Q1 FY2018 | Mar 31, 2018 | 53.2% | −4.3 |
| Q4 FY2017 | Dec 31, 2017 | 39.1% | −1.4 |
| Q3 FY2017 | Sep 30, 2017 | 53.9% | −5.2 |
| Q2 FY2017 | Jun 30, 2017 | 54.9% | – |
| Q1 FY2017 | Mar 31, 2017 | 57.5% | – |
| Q4 FY2016 | Dec 31, 2016 | 40.6% | – |
| Q3 FY2016 | Sep 30, 2016 | 59.1% | – |
See a number that looks wrong?